| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $155.0M | +28.9% |
| SG&A Expense | $59.9M | +27.3% |
| Operating Income | -$215.0M | -28.5% |
| Net Income | -$214.0M | -28.1% |
| EPS (Basic) | -$4.64 | -17.8% |
| EPS (Diluted) | -$4.64 | -17.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $61.6M | -55.6% |
| Current Assets | $110.8M | -61.4% |
| Total Assets | $115.1M | -60.7% |
| Current Liabilities | $34.3M | -10.6% |
| Total Liabilities | $39.0M | -6.9% |
| Stockholders' Equity | $76.1M | -69.7% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$185.0M | -48.6% |
| Capital Expenditures | $444K | -57.7% |
| Investing Cash Flow | $96.9M | +169.0% |
| Financing Cash Flow | $10.5M | -90.3% |
| Free Cash Flow | -$185.5M | -47.7% |